HomeIndustriesHealthcareEli Lilly’s Chart Gets Another Boost from Obesity Drug

Eli Lilly’s Chart Gets Another Boost from Obesity Drug

From diabetes to heart disease, the obesity drug Zepbound has been shown to have positive effects for other health ailments. Now, the company has a trial pointing to reduced sleep apnea severity. The health care giant’s stock has bounced on every drug-pipeline update, so Ben Lichtenstein decided to focus on the technical patters on Chart of the Day: Eli Lilly (LLY)

17 Apr 2024

SHARE

ON AIR
education
11:00 am
Your First Trade
replay
education
12:00 am
Your First Trade
REPLAY
education
12:30 am
Your First Trade
REPLAY
1:00 am
The Wrap
REPLAY
2:00 am
Fast Market
REPLAY
3:00 am
Next Gen Investing
REPLAY
4:00 am
Market Overtime
REPLAY
education
4:30 am
Inside the Mind of a Trader
REPLAY
education
5:00 am
Inside the Mind of a Trader
REPLAY
education
5:30 am
Inside the Mind of a Trader
REPLAY
6:00 am
Market Overtime
REPLAY
7:00 am
The Wrap
REPLAY
8:00 am
Fast Market
REPLAY
9:00 am
Next Gen Investing
REPLAY
education
10:00 am
Your First Trade
REPLAY
education
10:30 am
Your First Trade
REPLAY
ON AIR
education
11:00 am
Your First Trade
REPLAY
education
11:30 am
Your First Trade
REPLAY
education
12:00 pm
Your First Trade
REPLAY
education
12:30 pm
Your First Trade
REPLAY
education
1:00 pm
Your First Trade
REPLAY
education
1:30 pm
Your First Trade
REPLAY
education
2:00 pm
Your First Trade
REPLAY
education
2:30 pm
Your First Trade
REPLAY
3:00 pm
Market Overtime
REPLAY
4:00 pm
Fast Market
REPLAY
5:00 pm
Next Gen Investing
REPLAY
6:00 pm
The Wrap
REPLAY
7:00 pm
Market Overtime
REPLAY
8:00 pm
The Wrap
REPLAY
9:00 pm
Market Overtime
REPLAY
10:00 pm
Fast Market
REPLAY
11:00 pm
Next Gen Investing
REPLAY

Schwab Network's Newsletters

Daily insights for every investor